Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.64 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD5 | P21918 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PLEC | Q15149 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11242694 | 0.90 | PARP1 (0.60) | PARP1HTR3ATYMSMEN1USP2 | |
| SCHEMBL10955932 | 0.90 | PARP1 (0.60) | PARP1HTR3ATYMSDRD2DRD4 | |
| SCHEMBL10672758 | 0.86 | PARP1 (0.51) | PARP1HTR3ATYMSMEN1USP2 | |
| SCHEMBL29687934 | 0.78 | PARP1 (1.00) | PARP1HTR3AMTNR1AMTNR1B | |
| SCHEMBL742407 | 0.78 | PARP1 (1.00) | PARP1HTR3AMTNR1AMTNR1B | |
| SCHEMBL12628019 | 0.77 | NPC1 (0.55) | PARP1HTR3ADRD2DRD4DRD5 | |
| SCHEMBL743601 | 0.74 | PARP1 (1.00) | PARP1HTR3AMEN1USP2KMT2A | |
| Phosphoric Acid SCHEMBL29456911 | 0.72 | PARP1 (0.86) | PARP1HTR3AMTNR1AMTNR1B | |
| SCHEMBL6311706 | 0.72 | PARP1 (0.48) | PARP1HTR3AMEN1USP2KMT2A | |
| SCHEMBL13557123 | 0.71 | HTR3A (0.67) | PARP1HTR3AMEN1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-5466689-A | Analgesics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0610793-A1 | Tetracyclic morpholine derivatives and their use or analgesics | Takeda Chemical Industries, Ltd. (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5026869-A | Antidepressants; serotonin antagonists | ELI LILLY AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4983622-A | Antidepressants | ELI LILLY AND COMPANY (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0153083-B1 | 6-SUBSTITUTED-4-DIALKYLAMINOTETRAHYDROBENZ(C,D)INDOLES | ELI LILLY AND COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4576959-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4543415-A | Process for preparing tricyclic indoles | MERCK & CO., INC. (US) | 1985-09-24 | — | — | US | disclosed |
| US-4543415-A | Process for preparing tricyclic indoles | MERCK & CO., INC. (US) | 1985-09-24 | — | — | US | disclosed |
| EP-0153083-A2 | 6-Substituted-4-dialkylaminotetrahydrobenz(c,d)indoles | ELI LILLY AND COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | PARP1 3077/4885HTR3A 395/4885TYMS 2362/4885 |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | PARP1 3077/4885HTR3A 395/4885TYMS 2362/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | PARP1 2056/4885HTR3A 207/4885TYMS 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.